Evidence map›Paper›PMID 34568017›Full record

ReviewFrontiers in oncology2021

Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma.

Xinhe Zhang, Lin Guan, Haoyu Tian, Zilu Zeng, Jiayu Chen, Die Huang, Ji Sun, Jiaqi Guo, Huipeng Cui, Yiling Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Clinical andInfectious disorders drug targets · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xinhe ZhangGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Lin GuanGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Haoyu TianThe 3rd Clinical Department of China Medical University, Shenyang, China.
Zilu ZengGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Jiayu ChenGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Die HuangGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Ji SunGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Jiaqi GuoGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Huipeng CuiGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
Yiling LiGastroenterology Department, The First Affiliated Hospital of China Medical University, Shenyang, China.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a common cancer in the world, and its incidence is increasing yearly. Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection are important causes of HCC. Liver cirrhosis, age, sex, smoking and drinking, and metabolic risk factors will increase the risk of cancer in HBV/HCV patients. And viral load, APRI, FIB-4, and liver stiffness can all predict the risk of HCC in patients with viral infection. In addition, effective prevention strategies are essential in reducing the risk of HCC. The prevention of HCC involves mainly tertiary prevention strategies, while the primary prevention is based on standardized vaccine injections to prevent the occurrence of HBV/HCV. Eliminating the route of transmission and vaccination will lead to a decrease in the incidence of HCC. Secondary prevention involves effective antiviral treatment of HBV/HCV to prevent the disease from progressing to HCC, and tertiary prevention is actively treating HCC to prevent its recurrence.

Indexed as

hepatitis B virushepatitis C virushepatocellular carcinomapreventionrisk factors

Identifiers

PMID34568017
PMCPMC8458967
OpenAlexW3197767715

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.